ArticleOman medical journal2026
The Current and Future Burden of Metabolic Dysfunction-related Cancers in Arab Countries, 2022-2050.
Article in Oman medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The burden of cancers related to metabolic dysfunction in the Arab countries is not well defined. This study aimed to summarize the latest estimates for 10 cancers associated with metabolic dysfunction in the region and provide future projections to inform cancer control policies. Methods: We extracted estimates of new cancer cases and deaths for colon, liver, gallbladder, pancreas, breast, corpus uteri, ovarian, kidney, thyroid, and multiple myeloma cancers from the GLOBOCAN database for the year 2022. We present age-standardized incidence rates (ASIRs) and age-standardized mortality rates (ASMRs) for 2022 alongside projections for 2050. Results: In 2022, the 22 member countries of the Arab League reported a total of 502 959 new cancer cases. Of these, 218 746 (43.9%) cases were attributed to metabolic dysfunction. Breast cancer was the most commonly diagnosed, accounting for 43.7% of metabolic dysfunction-related cases, followed by liver cancer (16.8%) and colon cancer (10.4%). Projections indicate significant increases in incidence by 2050 for all studied cancers in the Arab region, with the largest relative increases expected in Gulf Cooperation Council countries, especially Kuwait, the UAE, and Qatar. Conclusions: Cancers related to metabolic dysfunction account for nearly half of the cancer burden in Arab countries, with marked regional differences. The projected rise in incidence and mortality by 2050 highlights the need for comprehensive, multisectoral cancer control policies implemented at the regional level and tailored to the cancer profiles of individual countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.